Cefovecin

Cefovecin

Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy category	do not administer to pregnant cat or during breeding or lactation period.
Routes of administration	dorsoscapular subcutaneous injection
ATCvet code	QJ01DD91 (WHO)
Legal status
Legal status	veterinary prescription only
Pharmacokinetic data
Protein binding	Dogs: 98.5%, Cats: 99.8%
Metabolism	none
Biological half-life	Dogs: 133 hours, Cats: 166 hours
Excretion	unchanged in urine/bile
Identifiers
IUPAC name (7R)-7-([(2Z)- 2-(2-amino- 1,3-thiazol- 4-yl)- 2-methoxyiminoacetyl]amino)- 8-oxo- 3-[(2S)-oxolan- 2-yl]- 5-thia- 1-azabicyclo[4.2.0]oct- 2-ene- 2-carboxylic acid
CAS Number	234096-34-5
PubChem (CID)	9578573
ChemSpider	7851662
UNII	0D1OL46ZIE
ChEMBL	CHEMBL2104475
Chemical and physical data
Formula	C17H19N5O6S2
Molar mass	453.49 g/mol
3D model (Jmol)	Interactive image
SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)\c3nc(sc3)N)[C@H]4OCCC4)C(=O)O
InChI InChI=1S/C17H19N5O6S2/c1-27-21-10(8-6-30-17(18)19-8)13(23)20-11-14(24)22-12(16(25)26)7(5-29-15(11)22)9-3-2-4-28-9/h6,9,11,15H,2-5H2,1H3,(H2,18,19)(H,20,23)(H,25,26)/b21-10+/t9-,11+,15+/m0/s1 Key:ZJGQFXVQDVCVOK-MSUXKOGISA-N
(what is this?)  (verify)

Cefovecin (INN) is an antibiotic of the cephalosporin class, licensed for the treatment of skin infections in cats and dogs. It is marketed by Zoetis under the trade name Convenia. It is the first single-dose injectable antibiotic for dogs and cats that assures owner compliance with dosing for the animal. It is used for the treatment of skin infections caused by Pasturella multocida in cats, and Staphylococcus intermedius/S. canis in dogs. The advantage of using injectable antibiotics is not missing a dose that can allow partially resistant microbes to recover during missed doses. The disadvantage is the durable presence of subtherapeutic concentrations in the weeks after the resolution of infections. This is associated with the development of resistance in microbes. It is effective, but should not be used in pregnant or lactating animals or in animals with a history of allergies to penicillin or cephalosporin drugs.^[1]

Approval and usage

Cefovecin was first authorized for use in the European Union in June 2006,^[2] and was approved for use in the United States in June 2008.^[3]

It is approved as a broad-spectrum, third-generation cephalosporin for subcutaneous injection lasting 14 days for treating skin and soft tissue infections.^[4]

Precautions

Contraindications include known allergies to cefovecin or antibiotics containing β-lactam rings such as penicillin or cephalosporins. Adverse reactions can include anaphylaxis. It is not for use in humans and should be kept out of reach of children. Individuals with similar known allergies should avoid dermal contact when handling the drugs.

Adverse reactions in dogs can include lethargy, decreased appetite, vomiting, diarrhea, blood in feces, and flatulence. Adverse reactions in cats can include vomiting, diarrhea, decreased appetite, lethargy, odd hyperactive behavior, and inappropriate urination. Mildly increased serum ALT and gamma glutamyl transferase have been noted.^[5]

The following adverse events were reported voluntarily during post-approval use of the product in dogs and cats: death, tremors/ataxia, seizures, anaphylaxis, acute pulmonary edema, facial edema, injection site reactions (alopecia, scabs, necrosis, and erythema), hemolytic anemia, salivation, pruritus, lethargy, vomiting, diarrhea, and inappetance..^[6]

Effectiveness

Cefovecin functions by interfering with cell wall synthesis. The chemical covalently binds to the so-called penicillin-binding proteins. Due to the high protein-binding of the chemical, it is not effective against Pseudomonas spp., or enterococci.

In drug studies, cefovecin administered to dogs was 92.4% effective against skin infections (secondary superficial pyoderma, abscesses, and infected wounds). In cats, it was 96.8% effective against skin infections.^[7]

References

1. Pfizer Animal Health. "Pfizer Convenia" (PDF). Pfizer. Retrieved 29 January 2013.
2. "European Public Assessment Report for Convenia (from the EMEA website)". Retrieved 2008-07-11.
3. "FDA Approves First and Only Single-dose Antibiotic for Dogs and Cats" (Press release). Pfizer Inc. 2008-06-30. Retrieved 2008-07-11.
4. Pfizer Animal Health. "Convenia". Pfizer. Retrieved 29 January 2013.
5. Pfizer Animal Health. "Pfizer Convenia" (PDF). Pfizer. Retrieved 29 January 2013.
6. Convenia Prescribing Information. "Convenia Prescribing Information" (PDF). Pfizer. Retrieved 18 October 2015.
7. Pfizer Animal Health. "Pfizer Convenia" (PDF). Pfizer. Retrieved 29 January 2013.

External links

• CID 23670874 from PubChem - Cefovecin sodium
• Official website by Pfizer